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Abstract
Human cord blood (CB) is enriched in circulating endothelial colony forming cells (ECFC) that 
display high proliferative potential and in vivo vessel forming ability. Since diminished ECFC 
survival is known to dampen the vasculogenic response in vivo, we tested how long implanted 
ECFC survive and generate vessels in three-dimensional (3D) type I collagen matrices in vitro and 
in vivo. We hypothesized that human platelet lysate (HPL) would promote cell survival and 
enhance vasculogenesis in the 3D collagen matrices. We report that the percentage of ECFC co-
cultured with HPL that were alive was significantly enhanced on days 1 and 3 post- matrix 
formation, compared to ECFC alone containing matrices. Also, co-culture of ECFC with HPL 
displayed significantly more vasculogenic activity compared to ECFC alone and expressed 
significantly more pro-survival molecules (pAkt, p-Bad and Bcl-xL) in the 3D collagen matrices 
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in vitro. Treatment with Akt1 inhibitor (A-674563), Akt2 inhibitor (CCT128930) and Bcl-xL 
inhibitor (ABT-263/Navitoclax) significantly decreased the cell survival and vasculogenesis of 
ECFC co-cultured with or without HPL and implicated activation of the Akt1 pathway as the 
critical mediator of the HPL effect on ECFC in vitro. A significantly greater average vessel 
number and total vascular area of human CD31+ vessels were present in implants containing 
ECFC and HPL, compared to the ECFC alone implants in vivo. We conclude that implantation of 
ECFC with HPL in vivo promotes vasculogenesis and augments blood vessel formation via 
diminishing apoptosis of the implanted ECFC.
Keywords
Endothelial colony forming cells (ECFC); Human platelet lysate (HPL); Three dimensional (3D) 
collagen matrix; Vasculogenesis; Apoptosis
INTRODUCTION
The progenitor cells for the endothelial lineage play critical roles in vascular homeostasis 
and regeneration in adult subjects [1,2]. Endothelial colony forming cells (ECFC) are 
derived from a rare circulating subset that may arise from resident endothelium of 
established blood vessels in man [2]. We have successfully isolated human peripheral blood 
(PB) or umbilical cord blood (CB) derived circulating ECFC that display a hierarchy of 
proliferative potential through the use of single cell clonogenic and functional assays [3–5]. 
Human CB derived ECFC also display de novo vessel forming ability in nude or Non-obese 
diabetic/ severe combined immunodeficient mice (NOD/SCID) in vivo after subcutaneous 
implantation of ECFC in type I collagen matrices and upon perfusion with host murine 
vessels, become a part of the systemic host circulation [6–9].
Previous studies have reported that human ECFC-derived vessels formed in subcutaneous 
implants were found as early as day 1 or 2 after implantation in NOD/SCID mice [10]. 
However, these premature vessels were not properly perfused with murine red blood cells of 
the host circulatory system at those early time points. Proof of human ECFC cell-lined 
vessel connection to host circulation system after 3–4 days of implantation in vivo was 
subsequently reported [10]. It has been reported that up to 60% of human umbilical vein 
endothelial cells (HUVECs) undergo apoptosis in the first 24 hours after suspension in 
collagen gels and there is further loss of vascular structures in 3D type I collagen matrices 
after 24 hours of culture [11]. In our previous study, we demonstrated that human CB ECFC 
containing collagen matrices displayed ECFC undergoing apoptosis on day 1 following 
implantation [12]. After 2–3 days, most ECFC died with only 1–3% of the total implanted 
cells demonstrating viability in the subcutaneous implants [12]. Since the stability of newly 
formed vessels requires systemic blood flow, these data suggest that implanted endothelial 
cells must survive at least 3–4 days in vivo to form a stable perfused capillary network 
connected to the host circulatory system.
The microvascular network has the intrinsic capacity to remodel itself through changes in 
endothelial cell differentiation, growth, migration, and matrix modification [13,14]. Previous 
studies have reported that cytokines, matrix proteins, and integrins are important factors in 
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capillary endothelial network formation and remodeling in various matrix models (Matrigel 
and type I collagen matrix systems) [7,15–20]. The absence of peri-endothelial support cells 
or lack of endothelial cell adhesion to matrix proteins causes destabilization and regression 
of capillary structures within Matrigel or 3D type I collagen matrices [16,17,21,22]. 
Apoptosis of endothelial cells has been observed in the context of dynamic capillary 
network remodeling in the various matrix models both in vitro and in vivo and is thought to 
play a necessary role for optimal network formation [17,21]. On the other hand, the 
generation of anti-apoptotic signals is also required to maintain integrity of the vascular 
network following realignment of certain matrix proteins and cell-cell or cell-matrix 
interactions during the process [17,21]. Thus, understanding the balance between pro-
apoptotic and pro-survival signals is a critical point in capillary structure formation and the 
remodeling process.
Apoptosis is a cellular process in tissue development that generally culminates with the 
sequential activation of caspases, the cysteine proteases for cleavage of proteins [23,24]. 
There are two pathways that result in apoptosis depending on the apoptotic signal. The 
extrinsic pathway is initiated by ligand binding to membrane receptors of the death receptor 
family, whereas the intrinsic pathway is mediated by stress-mediated damage such as 
alterations in temperature, osmolality, DNA damaging agents, free radical generation 
compounds, removal of nutrients, and oxygen deprivation [23,24]. The activation of the two 
pathways leads to the same type of apoptotic response, causing release of cytochrome c 
(Cyt-C) from mitochondria and activation of the executioner caspase-3 [23,24]. In the 
normal state, Akt activation (phosphorylated Akt, pAkt) by various growth factors induces 
cell survival via protection of mitochondrial integrity and inhibition of Cyt-C release 
[25,26]. Akt has also been reported to stimulate the expression of anti-apoptotic Bcl-2 
proteins, such as Bcl-xL that prevents permeablization of the mitochondrial membrane by 
inhibiting activation of Bax/Bak [27]. However, under apoptotic stimulation, pro-apoptotic 
members of the Bcl-2 family (Bax, Bak and Bad) are activated and induce the release of 
Cyt-C from mitochondria by binding and inactivating anti-apoptotic proteins [28]. As the 
penultimate event, caspase-3 is activated to cleaved-caspase-3 to generate all the 
biochemical and morphologic hallmarks of cell apoptosis.
Platelets regulate the balance between apoptosis and cell survival in numerous cells involved 
in the repair of injured tissues [29,30]. Since platelets have a critical role in regulation of cell 
death and survival and contains various growth factors and cytokines [29–31], we 
hypothesized that human platelet lysate (HPL) would increase ECFC survival and enhance 
ECFC vascularization by modulating the balance between apoptosis and cell survival of 
ECFC in 3D collagen matrices.
MATERIALS AND METHODS
Culture of human umbilical cord blood (UCB) derived ECFC
ECFC were isolated and cultured as previously described [3]. ECFC colonies appeared 
between 5 and 22 days of culture and were noted to form colonies of adherent cells with 
cobblestone morphology. After approximately 10 days of culture, the ECFC-derived ECs 
were released from the culture dish by TrypLE™ Express (Gibco) and replated onto 25/75 
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cm2 tissue culture flasks pre-coated with Type I rat-tail collagen (BD Biosciences) for 
subsequent passage.
Preparation of three-dimensional (3D) collagen matrices
All of the type I collagen oligomers and associated polymerization reagents were purchased 
from GeniPhys [32]. Stock oligomer was diluted in 0.01N hydrogen chloride (HCl) and 
neutralized according to manufacturer’s recommendations to achieve a final oligomer 
concentration of 1.37mg/ml (200Pa matrix stiffness). ECFC (1 × 105/ 60µl or 1 × 106/ 
250µl) were suspended in the collagen solution with or without human platelet lysate (HPL- 
10% of final concentration) at 4°C. The HPL was purchased from Gemeinnützige 
Salzburger Landeskliniken Betriebsges (SALK) Graz, Austria. The HPL was prepared from 
pooled platelet-rich plasma derived from a minimum of 40 whole blood donations [33]. The 
collagen-cell suspensions were plated on 96-well or 48-well plates and allowed to 
polymerize at 37°C for 30 minutes and covered with complete endothelial cell growth 
medium (EGM-2, Lonza) with 10% defined fetal bovine serum (Hyclone) for incubation for 
one to three days at 37°C, 5% CO2.
Toluidine blue staining of 3D collagen matrices and quantification of in vitro vascular 
structures
For analysis of in vitro vascular structure formation in 3D collagen gel, cellularized collagen 
matrices were fixed with 4% paraformaldehyde for 20 minutes on Day 1 or Day 3 after 
culture. The matrices were stained with 0.1% toluidine blue O dye (30% methanol) for 25 
minutes at room temperature and washed with PBS for 30 minutes for three times at room 
temperature. Vascular structures including vacuoles, lumens and tube formation were 
quantified using ImageJ image analysis software (National Institutes of Health (NIH)). 
Vacuoles and lumens were defined as areas completely surrounded by a toluidine blue 
labeled endothelial cell membrane. A single image of the entire well was captured at a depth 
of 10 microns from the surface of the matrix and then additional places 150 microns apart 
for each of triplicate samples of each group. Images of vascular structures were captured at 
10× and 20× levels of magnification.
Assessment of apoptosis of ECFC in 3D collagen matrices
Apoptosis was assessed by examining the percentage of human CD31+ ECFC that bound 
Annexin V and propidium iodide and was performed as per the manufacturer’s instruction 
(Apoptosis Detection kit; eBioscience). ECFC (1 × 105/ 60µl) were suspended in collagen 
matrices with/without HPL (10% of final concentration), with dimethyl sulfoxide (DMSO) 
vehicle (same volume of solvent for each inhibitor) or with signaling pathway inhibitors, 
plated in 96-well plates and incubated for one to three days as above. As previously 
described [12], matrices were recovered from one to three days after culture and incubated 
in 250 µl Collagenase Type I (0.25%) (Stemcell technology) for 20 minutes at 37°C. Akt1 
inhibitor (A-674563) and Bcl-xL inhibitor (ABT-263/Navitoclax) were purchased from 
Selleckchem and Akt2 inhibitor (CCT128930) was purchased from Santa Cruz 
biotechnology. Cell dissociation buffer was added to stop the enzymatic reaction 
(Invitrogen). Cells were centrifuged at 500 g for 5 minutes at room temperature. Cell pellets 
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were suspended in staining buffer and stained with anti-human CD31 antibody conjugated to 
phycoerythrin (PE) for 15 minutes (clone WM-59, BD Biosciences Pharmingen). Cells were 
incubated and stained for Annexin V-allophycocyanin (APC) and propidium iodide (PI) in 
binding buffer for 10 minutes at room temperature in the dark. Stained cells were analyzed 
by FlowJo software. Three different clones of ECFCs were analyzed in each experiment and 
each experiment repeated one or two times.
Western Blot
Cellular protein lysates were extracted from the ECFC in collagen matrices and 
electrophoresed using sodium dodecyl sulfate–polyacrylamide matrix electrophoresis (SDS-
PAGE), transferred to nitrocellulose, and probed with monoclonal antibodies that included 
anti-human Bcl-xL (clone 54H6, Cell signaling), cleaved caspase-3 (clone 3G2, Cell 
signaling), Akt1 (clone 2H10, Cell signaling), Akt2 (clone L79B2, Cell signaling), phospho-
Akt1 (pAkt1 Ser473) (clone D7F10, Cell signaling), phospho-Akt2 (pAkt2 Ser474) (clone 
D3H2, Cell signaling) and phospho-Bad (pBad Ser136) (clone D25H8, Cell signaling). 
Anti-human β-actin (mAbcam 8226, Abcam) and GAPDH (clone 14C10, Cell signaling) 
antibodies were used to probe for loading control proteins. Three different clones of ECFCs 
were analyzed in each experiment on at least two occasions.
Implantation of human cord blood derived ECFC into NOD/SCID mice
Cellularized matrix implants were cast as noted above. Cultured ECFC (1 × 106/ 250µl) 
were suspended in the collagen mixture with or without HPL (10% of final concentration). 
Then 250 µL of the cell suspension was pipetted into one well of a 48-well tissue culture 
plate, allowed to polymerize at 37°C for 30 minutes, and covered with 500 µL EGM-2 
medium for 30minute incubation at 37°C, in 5% CO2. Matrices were implanted into the 
flanks of anesthetized 6- 9-week-old NOD/SCID mice. After 5 days or 14 days, the mice 
were sacrificed; the grafts were excised and analyzed by histology and 
immunohistochemistry (N=6 each group) as previously described [5].
Histology and Immunohistochemistry
Sections were stained as previously described [5]. Briefly, paraffin-embedded tissue sections 
were deparaffinized and then either directly stained with hematoxylin and eosin (H&E) or 
immersed in retrieval solution (Dako) for 20 minutes at 90–99°C. Slides were incubated at 
room temperature for 30 minutes with anti-human CD31 antibody (clone JC70/A, Abcam) 
followed by a 10-minute incubation with LASB2 link-biotin and streptavidin-HRP (Vector 
Laboratories), then developed with DAB (Vector Laboratories) solution for 5 minutes. 
Slides were analyzed by microscope under 20× magnification.
Statistical Analysis
Results are expressed as mean ± the standard error of the mean (SEM) for the study 
variables. The assessment of apoptosis of ECFC, in vitro vascular structure quantification 
and the quantification of western blot data points (ECFC versus ECFC+HPL), western blot 
data points (ECFC treated with DMSO, Akt1 inhibitor, Akt2 inhibitor or Bcl-xL inhibitor) 
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were assessed by unpaired t-test. A statistically significant difference was set at *P<0.05, 
**P<0.001, or ***P<0.0001.
RESULTS
Human cord blood (CB) derived ECFC with human platelet lysate (HPL) significantly 
reduces apoptosis of ECFC in three dimensional (3D) collagen matrices
Our previous study demonstrated that cultured ECFC started undergoing apoptosis on day 1 
and a significant majority of ECFC died on day 2 and 3 in 3D collagen matrices after 
implantation [12]. We first examined whether the presence of HPL altered ECFC 
proliferation in 3D collagen matrices and observed no effect (data not shown). We then 
tested whether the co-culture of ECFC with HPL would decrease apoptosis of human CB 
ECFC in the 3D collagen matrices in vitro. After 1–3 days, ECFC were recovered from 3D 
collagen matrices and assessed for apoptosis of ECFC stained with anti-human CD31, 
annexinV and propidium iodide (PI). CD31+ ECFC were selected from the total cell 
population and separated into annexinV+/− and PI+/− expressing subsets (Supplementary Fig. 
1). Cultured ECFC without HPL started undergoing apoptosis on day 1 and a significant 
amount of the cells died by day 3 after matrix formation in vitro (Fig 1a). In contrast, ECFC 
co-culture with HPL revealed a significantly higher percentage of the AnnexinV−/PI− viable 
cell population compared to the control (ECFC alone) (Fig. 1a). We investigated whether 
co-culture of ECFC with HPL would enhance more vascular structures in 3D collagen 
matrices in vitro. ECFC-derived vascular structures were defined as endothelial cells with 
vacuoles and lumenized structures were defined as areas completely surrounded by a 
toluidine blue labeled endothelial cell membrane (Fig. 1b). A significantly greater average 
number of vascular structures (Fig. 1c) and total luminal area of vascular structures (mm2) 
(Fig. 1d) were quantified in ECFC + HPL group compared to the control group on both day 
1 and 3 of the in vitro study. These data suggest that ECFC + HPL co-culture significantly 
promotes vasculogenesis by inducing greater cell survival of ECFC in 3D collagen matrices 
in vitro.
Co-culture of ECFC with HPL modulates the balance between apoptosis and cell survival 
in 3D collagen matrices
Knowing that HPL treatment can modulate the balance between apoptosis and cell survival 
[29,30], we subsequently tested whether co-culture of ECFC with HPL would alter the 
protein expression level of pro-apoptotic, anti-apoptotic and pro-survival molecules in vitro. 
On day 1 and 3 after casting the matrices, expression of pro-survival molecules (Akt1 and 
phosphorylated Akt1 (pAkt1)) and an anti-apoptotic molecule (Bcl-xL) were upregulated in 
co-culture of ECFC with HPL compared to ECFC without HPL group (Fig. 2a and b). The 
pro-apoptotic molecule, Bad was phosphorylated (pBad) to an inactive form that blocks 
apoptosis and the expression level of pBad was upregulated in co-culture ECFC with HPL 
compared to control group on day 1 and 3 in vitro (Fig. 2a and b). The expression level of 
active cleaved caspase-3 was enhanced in co-culture of ECFC with HPL compared to 
control samples on day 1 and 3 (Fig. 2a and b). We also examined protein expression level 
of Akt2 and pAkt2, but these proteins were not detected in either group on day 1 or 3 (data 
not shown). Since HPL contains various cytokines and growth factors that are involved in 
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pro-survival and anti-apoptotic signaling [34], HPL may induce more pro-survival/anti-
apoptotic signaling to resist the apoptotic stimuli that activities of caspase-3 (cleaved 
caspase-3). These data suggest that co-culture of ECFC with HPL in vitro promotes cell 
survival of ECFC by modulating the balance between pro-apoptotic and anti-apoptotic/pro-
survival molecules.
Co-implantation of ECFC with HPL significantly enhances vasculogenesis of ECFC in vivo
Co-culture of ECFC with HPL induced more formation of vascular structures in vitro in 3D 
collagen matrices compared to control matrices (Fig 1). We subsequently tested whether co-
implantation of ECFC with HPL would promote vasculogenesis in an in vivo model. 
Specific anti-human CD31 antibody staining revealed human CB ECFC cell-lined 
microvessels that were perfused with murine red blood cells in the grafts (Fig 3a). The 
quantification of murine erythrocyte-containing human CD31+ microvessels revealed a 
significant increase of average vessel numbers (Fig. 3b) and total vessel area (mm2) (Fig. 
3c) in ECFC + HPL implants compared to ECFC alone implants. In addition, the size 
distribution of the microvessels differed between ECFC implants with HPL and ECFC alone 
implants (Fig. 3d). Noticeably, only co-implantation of ECFC with HPL gave rise to the 
largest vascular elements (1001–4000µm2). These data suggest that co-implantation of 
ECFC with HPL enhanced vasculogenesis in vivo as evidenced by more ECFC-derived 
vessel formation with an enlarged vascular bed area.
Inhibition of pro-survival/anti-apoptotic signaling enhances apoptosis of ECFC by 
modulating protein expression of pro-survival molecules in 3D collagen matrices
Since ECFC cell survival was significantly increased when ECFC were co-cultured with 
HPL by balancing the anti-apoptotic/pro-survival (Akt1, pAkt1, pBad and Bcl-xL) and pro-
apoptotic signals (cleaved caspase-3), we evaluated whether inhibition of these pro-survival 
and anti-apoptotic molecules would alter cell survival of ECFC in 3D collagen matrices. Akt 
is a critical regulator of PI3K-mediated cell survival [35]. Since, Akt1 and Akt2 are the 
upstream molecules in PI3K-mediated cell survival and have been reported to display 
compensatory functions between isoforms [36,37], Akt1 and Akt2 inhibitors were selected 
to examine the importance of these signaling pathways on ECFC pro-survival signaling. 
Akt1 inhibitor blocks the phosphorylation of the Akt downstream target pBad to result in 
increased apoptosis [38,39]. Akt2 inhibitor has been reported as a novel small molecule that 
inhibits cell proliferation by inducing cell cycle arrest and triggers apoptosis [40]. Also, the 
inhibitor of Bcl-xL was selected for blocking anti-apoptotic signaling in ECFC in 3D 
collagen matrices. Bcl-xL inhibitor binds to apoptosis suppressor Bcl-xL and prevents 
binding to the apoptotic effectors Bax and Bak proteins [41,42]. The concentration of each 
inhibitor was chosen based on dose-dependent optimization experiments (Supplementary 
Fig. 2). ECFC and ECFC + HPL groups were treated with DMSO as vehicle control, 2µM of 
Akt1 inhibitor (Fig.4a), 2 µM of Akt2 inhibitor (Fig.4b) and 20nM of Bcl-xL inhibitor (Fig.
4c). The percentage of the Annexin V−/PI− viable population was significantly reduced in 
both groups of ECFC alone and ECFC with HPL when exposed to the Akt1 inhibitor on 
both day 1 and 3 of culture. While cell survival of ECFC alone group was significantly 
decreased on day 1, both groups of ECFC and ECFC + HPL displayed zero cell survival on 
day 3 when treated with the Bcl-xL inhibitor. Akt2 inhibitor treatment significantly reduced 
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cell survival of ECFC alone group on day 1 and 3. However, there was not a statistical 
significant difference in cell survival of ECFC in the ECFC + HPL group when treated with 
Akt2 inhibitor on day 1 and 3 because of high variability among the repeated experiments. 
As a result, only Akt1 inhibition of ECFC displayed a significant reduction of ECFC cell 
survival in both groups on day 1 following culture. These results implicate the Akt1 pathway 
as the most important pro-survival pathway promoting ECFC survival in the 3D matrices.
Next, we examined whether the inhibitor treatments would alter the protein expression level 
of pro-survival/anti-apoptotic or pro-apoptotic molecules in ECFC in 3D collagen matrices 
on day 1. We tested only day 1 samples because cell survival of ECFC was close to zero by 
all inhibitor treatments on day 3. When treated with the Akt1 inhibitor, pBad (inactive form 
that blocks apoptosis) was barely detected in ECFC alone group and significantly decreased 
in ECFC + HPL group compared to DMSO control group. The level of Bcl-xL (anti-
apoptotic molecule) was not changed in both co-culture of ECFC and ECFC + HPL matrices 
with the inhibitor compared to DMSO control samples. When exposed to the Bcl-xL 
inhibitor, the level of pBad and Bcl-xL was significantly decreased in the both groups 
compared to DMSO controls. On the other hand, Akt2 inhibition caused a significant 
increase of expression level of Akt1/ pAkt1, Bcl-xL (anti-apoptotic molecule) and pBad 
(inactivated pro-apoptotic molecule) in both groups compared to DMSO group (Fig. 5). 
Cleaved caspase-3 (pro-apoptotic molecule) was increased with treatment of the three 
inhibitors in ECFC alone group compared to ECFC with DMSO group (Fig. 5b). However, 
cleaved caspase-3 expression was not changed in ECFC + HPL groups with the three 
inhibitors compared to ECFC + HPL treated with DMSO samples (Fig. 5c). Thus, inhibition 
of Akt1 and Bcl-xL (pro-survival/ anti-apoptotic molecules) promotes apoptosis of ECFC by 
decreasing pBad (inactivated pro-apoptotic molecule) and Bcl-xL (pro-survival molecule), 
which are Akt downstream substrates, in both ECFC alone and ECFC + HPL 3D groups. In 
summary, only Akt1 inhibition significantly diminished cell survival of ECFC by decreasing 
protein level of pBad in co-culture of ECFC with HPL, even though cleaved caspase-3 
expression was not concomitantly changed.
In addition, we also determined that ECFC treated with the Akt1, Akt2 and Bcl-xL 
inhibitors on day 1 and 3 displayed significantly diminished vascular structures on day 1 and 
absence of vascular structures on day 3 (date not shown). Collectively, these observations 
have demonstrated that inhibition of the Akt1 signaling pathway significantly diminished 
cell survival and vasculogenesis of ECFC by altering expression level of pro-apoptotic and 
anti-apoptotic/pro-survival molecules.
DISCUSSION
The microvascular network has dynamic structural plasticity. Vasculogenesis, angiogenesis 
and microvascular remodeling are complex processes following endothelial cell growth, 
migration and differentiation [43–45]. Many of theses in vivo processes can be modeled and 
examined in vitro. Human CB ECFC or human umbilical vein endothelial cells (HUVEC) 
participate in cell-cell and/or cell-matrix interactions and form capillary network within the 
first 24hrs on 2D Matrigel coated dishes. The capillary network formation shows 
tremendous structural plasticity and dynamic processes of not only new network formation 
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but also network regression. By blocking cell-matrix interactions with colchicine or anti-
human avb3 antibody, HUVEC failed to form a capillary network and a significant increase 
of endothelial cell death was observed [21]. Thus, cell-matrix interactions are necessary for 
cell viability and the formation of a capillary network on Matrigel coated dishes [21,31]. 
Bcl-2 over expression in HUVEC enhanced cell viability and promoted stabilization of the 
capillary network formed on Matrigel [21]. This study suggested that the formation of 
capillary networks is dependent on the balance between pro-apoptotic and pro-survival of 
endothelial cells on 2D Matrigel substrates. We suggest that the balance between pro-
apoptotic and anti-apoptotic/pro-survival signals play a critical role in promoting cell 
survival of ECFC and enhancing vasculogenesis when ECFC are co-implanted with HPL in 
in vitro and in vivo models (Fig. 1, 2 and 3).
Previous studies have been reported that HPL contains various cytokines and growth factors 
that are involved in various cellular events, particularly cellular migration, proliferation, 
differentiation, extracellular matrix organization and remodeling, and cell survival 
[31,34,46,47]. Growth factors in HPL, especially, VEGF and angiopoietin-1, stimulate Akt 
to promote cell survival and ensure adequate vascular development in cardiovascular 
functions [48–53]. Akt also has been reported to stimulate the expression of anti-apoptotic 
Bcl-2 proteins, such as Bcl-xL through the activation of NF-κB [27,50]. Constitutive 
activation of Akt signaling protects cardiomyocytes against apoptosis [54]. In addition, 
chronic activation of Akt/PI3K pathway in endothelial cells enhances cell survival of 
endothelial cells (ECs) and promotes more vasculogenesis of ECs in absence of growth 
factors and serum [55]. Since Akt1 is generally the predominant expressed isoform (Akt1, 
Akt2 and Akt3) and compensates Akt2 functions for the inhibition of Akt2 (Ak2 knockout) 
[36,37], such compensation may explain the why inhibition of Akt2 may not effectively alter 
expression of pro-survival/anti-apoptotic survival signaling molecules in the ECFC in 3D 
matrices (Fig.4 and 5). Only Akt1 inhibition significantly decreased the downstream targets, 
pBad and significantly diminished cell survival of ECFC on both day 1 and day 3 in our in 
vitro model. Thus, growth factors in HPL may enhance cell survival of ECFC by activating 
Akt1 and enhancing expression of pro-survival/anti-apoptotic molecules (pAkt1, pBad and 
Bcl-xL) against the apoptotic signal (cleaved caspase-3) mediated by environmental stress in 
our experimental models.
CONCLUSIONS
In summary, we have demonstrated that co-implantation of human cord blood ECFCs with 
HPL improves cell survival of ECFC and promotes robust formation of human ECFC-
derived microvessels with increased average vessel number, total vessel area and enlarged 
vessel sizes in vivo. By activating Akt1 pro-survival signaling in the ECFC, HPL modifies 
the balance of pro-apoptotic and anti-apoptotic/ cell survival signaling in the implanted cells 
to enhance vasculogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Human platelet lysate (HPL) significantly increases ECFC survival in collagen 
gel.
• ECFC with HPL significantly promotes vasculogenesis of ECFC in vitro and in 
vivo.
• HPL modulates protein expression of pro-survival molecules in Akt1 signaling.
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Figure 1. Co-culture of ECFC with human platelet lysate (HPL) diminishes apoptosis of ECFC 
in 3D collagen matrices in vitro
(a) The Annexin V−/PI− viable population of co-cultured ECFC with HPL was significantly 
higher on day 1 and 3 compared to ECFC alone culture. N=3 *P < 0.05. (b) Representative 
images of vascular structures of ECFC cultured with or without HPL in collagen matrices on 
day 1 and 3 (white arrows indicate the structures and small boxes indicates representative 
counted structures). Scale bar represents 0.05µm. Co-culture of ECFC with HPL resulted in 
a significant increase in (c) the average number of vascular structures per collagen matrix 
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surface area and (d) total luminal area of vascular structures per matrix surface area (mm2) 
compared to controls. N=10 each group *P < 0.05, **P<0.001 or ***P<0.0001.
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Figure 2. Human platelet lysate (HPL) in ECFC co-culture stimulates protein expression of 
apoptotic/ cell survival related molecules
(a) Representative immunoblots of pro-survival (Akt1, pAkt1, pBad and Bcl-xL) and 
apoptotic (cleaved caspase-3) proteins from ECFC and ECFC with HPL in 3D matrices. 
Lower panels show quantification of repeated experiments on day 1 (b) and day 3(c) after 
culture (protein expression levels were normalized using β-actin). Pro-survival molecules 
and apoptotic molecule were significantly upregulated on co-culture of ECFC with HPL 
compared to ECFC alone on day 1 and day 3. N=2 each group ns=no significance, *P < 0.05 
or **P<0.001.
Kim et al. Page 18
Microvasc Res. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Co-implantation of ECFC with HPL induces the formation of functional vessels in vivo
(a) Human ECFC-derived vessels were identified by rat anti-human CD31 staining (white 
arrows indicate ECFC-derived CD31+ vessels). The two top panel images show 
representative images of ECFC-derived human CD31+ vessels. The two lower panel images 
show representative images of ECFC with HPL derived human CD31+ vessels. Scale bar 
represents 10µm. There was a significant increase in (b) average vessel numbers per unit 
sectional area and (c) total vessel area (mm2) per unit sectional area in the ECFC with HPL 
implants. (d) In addition, only co-implantation of ECFC with HPL formed the largest sized 
vessels (# indicates 1001–4000µm2) in the size distribution of hCD31+ microvessels 
perfused with murine red blood cells. N=10 mice each group *P < 0.05 or **P<0.001.
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Figure 4. Inhibition of pro-survival molecules reduces cell survival in 3D collagen matrices on 
day 1 and day 3
The Annexin V−/PI− viable population of inhibitor treatment of ECFC alone or ECFC with 
HPL in 3D collagen matrices on day 1 and day 3: DMSO as vehicle control, (a) Akt1 
inhibitor, 2µm, (b) Akt2 inhibitor 2µm and (c) Bcl-xL inhibitor 20nM. Percentage of 
Annexin V−/PI− viable population was significantly decreased by inhibition of Akt1, Akt2 
and Bcl-xL. Of note, the most profound decrease in viability was observed in the ECFC + 
HPL matrices that contained the Akt1 inhibitor on day 1. N=3 each group*P < 0.05 or 
**P<0.001.
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Figure 5. Inhibition of pro-survival molecules affects protein expression of molecules involved in 
the apoptotic/cell survival signaling in 3D collagen matrices
(a) Representative immunoblots of inhibitor treatment of ECFC or ECFC with HPL in 3D 
collagen matrices (DMSO as vehicle control, Akt1 inhibitor, 2µm, Akt2 inhibitor 2µm and 
Bcl-xL inhibitor 20nM). Lower panels show quantification of repeated experiments of the 
inhibitor treatment ECFC alone (b) and ECFC with HPL (c) in 3D collagen matrix on day 1 
after culture (protein expression levels were normalized using GAPDH). N=2 each group *P 
< 0.05, **P<0.001 or ***P<0.0001.
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